Pd-l1 variant immunomodulatory proteins and uses thereof
AssigneeAlpine Immune Sciences, Inc.
InventorsRyan Swanson, Michael Kornacker, Mark F. Maurer, Dan Ardourel, Daniel William Demonte, Joseph L. Kuijper
Life of this patent
Estimating the term…
Abstract
Provided herein are immunomodulatory proteins comprising variant PD-L1 and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
Claims66
A polypeptide comprising an amino acid sequence comprising at least 90% identity to SEQ ID NOs:
- 30, 55, 309, or 1728, wherein the polypeptide comprises one or more amino acid modifications at one or more positions corresponding to position(s) selected from 45, 43, 6, 10, 11, 14, 15, 16, 17, 18, 19, 20, 22, 23, 26, 27, 28, 33, 35, 36, 40, 41, 44, 46, 47, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 60, 64, 65, 68, 71, 72, 73, 74, 75, 78, 79, 83, 85, 89, 90, 93, 97, 98, 99, 101, 102, 103, 104, 106, 110, 111, 112, 113, 117, 119, 120, 121, 124, 129, 130, 131, 134, 137, 138, 144, 148, 149, 150, 155, 158, 160, 163, 165, 167, 170, 171, 173, 175, 176, 177, 179, 180, 183, 185, 188, 189, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 206, 207, 213, or 221, with reference to the numbering of SEQ ID NO:30.
(canceled)
(canceled)
17-24. (canceled)
(canceled)
(canceled)
(canceled)
43-48. (canceled)
(canceled)
55-61. (canceled)
(canceled)
(canceled)
-76. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-91. (canceled)
(canceled)
-97. (canceled)
Dependencies are inferred from the claim text.